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Network Meta-aNalysis of Various treatMeNt strategies iN 
resistaNt HyPerteNsioN
Makai P, intHout J, Grutters JP, Deinum J, Jenniskens K, van der Wilt GJ
Radboudumc, Nijmegen, The Netherlands
Objectives: Currently, the most commonly applied approach to treatment of resist-
ant hypertension (TRH) is adding on mineralocorticoid receptor antagonists (MRAs) 
such as spironolactone to existing medication therapy. Newer treatment alterna-
tives for treating resistant hypertension were developed, however comparative 
effectiveness of these add-on strategies and MRAs is not established. Our objective 
is to perform a network-meta analysis of add-on treatment alternatives for MRAs 
in TRHTN and thus establish comparative effectiveness in terms of SBP and DBP 
reduction. MethOds: Recent meta-analyses for renal denervation (RDN) and placebo 
effect were supplemented with a systematic search for MRAs in TRHTN. Newer renal 
denervation articles were identified using Pubmed searches. Search terms included 
Randomized control trials (RCT), TRH, MRAs. We Independently extracted data using 
a pre-defined data extraction form, including Cohrane study quality indicators and 
the GRADE criteria. Network meta-analysis techniques were used to compare the 
effects of add-on treatment alternatives for TRHTN, using spironolactone as a com-
mon comparator. Results: We identified 16 articles which met our inclusion criteria. 
The results show that lack of add-on medication therapy leads to markedly higher 
blood pressure measurements than spironolactone, office SBP 24 [95% CI 2; 48] DBP 
7.4 [-2.9; 18]. While add-on placebo medication results in significantly higher blood 
pressure than add-on spironolactone, SBP 19 [5.7; 32] DBP 8.3[2.3; 14], add-on spirono-
lactone’s blood pressure reducing effects equal those of add-on sham operations SBP 
0.58 [-28; 29] DBP 0.36 [-12; 13]. cOnclusiOns: Currently, no active, add-on treatment 
strategy for TRHTN seems more effective than spironolactone. In addition, being the 
only effective active treatment strategy, research into future medicinal alternatives 
in TRHTN should use spironolactone as an active comparison, and as an obligatory 
background drug when investigating the effectiveness of device-based alternatives. 
Furthermore, trials investigating device-based alternatives such as renal denervation 
should always include sham procedure as a comparator.
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asPiriN Versus CloPidogrel iN PatieNts witH aCute MyoCardial 
iNfarCtioN: a Cost aNd effeCtiVeNess CoMParisoN froM BeijiNg 
MediCal iNsuraNCe dataBase
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1Peking University, Beijing, China, 2Bayer, Beijing, China
Objectives: To compare the cost and effectiveness of aspirin with that of clopi-
dogrel in acute myocardial infarction(AMI) patients from data of Beijing medical 
insurance database MethOds: We randomly selected 10% of patients diagnosed 
as AMI the first time during January 2012- December 2012 and then followed their 
inpatient records and prescription records to September 2013 from Beijing medical 
insurance database. We divided these patients into 5 groups according to their drug 
utilization records during the observation period. 1239 patients were divided into 
5 groups according to the proportion of aspirin prescription by 100.0%, 60.1-99.9%, 
40.0-60.0%, 0-39.9% and 0(clopidogrel only). We compared the rate of recurrences, 
cost of anti-platelet drugs and rate of hemorrhage events in different drug utiliza-
tion groups. The Kruskal-Wallis test and Bartlett’s test were used in the analy-
sis. Results: 1239 patients were identified(age 65.69±15.51, male 73.69%), 63 (2.54%) 
patients used aspirin only, 761 (61.42%) patients used aspirin more(60-100%), 289 
(23.33%) patients used 40-60% aspirin, 116 (9.36%) patients used aspirin 0-40% and 
10 (0.83%) patients used clopidogrel only. The MI recurrence rates for patients of 
different prescription groups were significantly different(p< 0.01), patients with only 
aspirin utilization recurred less than that of patients with 60-100% aspirin and 
40-60% aspirin prescription, patients with 0-40% aspirin prescription recurred less 
than that of patients with 60-100% aspirin prescription. The cost of anti-platelet 
drugs for patients of different drug groups was significantly different(p< 0.01), The 
hemorrhage rate of patients with only aspirin prescription was higher than that of 
patients with two drugs. cOnclusiOns: A small proportion of AMI patients used 
only one drug for anti-platelet treatment, while most patients used both aspirin and 
clopidogrel. Patients who used aspirin only had lower cost of anti-platelet drugs, 
lower rate of recurrence and higher rate of hemorrhage events. Further studies 
on cost-effectiveness for aspirin and clopidogrel would provide moret evidence.
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Objectives: To evaluate the burden to patients and the healthcare system associ-
ated with a new cardiovascular event (CVEs) up to 3 years post-new CVE among 
high-risk hyperlipidemia patients. MethOds: Using the IMS LifeLink PharMetrics 
Plus commercial claims database, this retrospective cohort study included high CV 
risk hyperlipidemia patients with and without a new CVE between 01/01/2006 and 
06/30/2012. CVEs included primary inpatient claims for myocardial infarction (MI), 
unstable angina (UA), ischemic stroke (IS), transient ischemic attack, revascularization 
and heart failure. Patients were stratified into two CV risk cohorts: history of cardio-
vascular disease (CVD) [MI, UA, coronary artery bypass graft, percutaneous coronary 
intervention, IS] and coronary heart disease risk equivalent (CHD RE) [peripheral 
artery disease, abdominal aortic aneurysm, coronary artery disease, diabetes, dys-
lipidemia]. Propensity score matching was applied to compare the burden among 
patients with and without a new CVE, ranging from 1 month through 3 years post-CVE 
date. Results: Using the IMS LifeLink PharMetrics Plus commercial claims data-
base, this retrospective cohort study included high CV risk hyperlipidemia patients 
ducted during a review of the company’s submission (CS) to the National Institute for 
Health and Care Excellence (NICE) Single Technology Appraisal programme for the 
oral direct thrombin inhibitor, dabigatran. MethOds:: Randomised controlled trials 
(RCTs) for inclusion were identified using the CS for dabigatran (as part of Technology 
Appraisal [TA]327), and two similar submissions for rivaroxaban (TA261 and TA287). 
RCTs were assessed for comparability based on patient population, disease severity, 
and treatments received. A Bayesian MTC was conducted, and fixed and random 
effects models were explored. Odds ratio (OR) was chosen as the summary statistic for 
VTE recurrence and major bleed. Results: The network of 9 RCTs formed a “radiating 
star”. The fixed effects model had the lowest deviance information criterion (DIC) for 
VTE recurrence and major bleed and so was chosen as the best-fitting model. There 
was reasonable agreement between the number of unconstrained data points and 
the residual deviance for both outcomes. Results compared to dabigatran were (OR> 1 
favours dabigatran): VTE recurrence LMWH OR 0.96 (95% Credible Interval [95%CrI]: 
0.15–3.37), rivaroxaban OR 1.29 (95%CrI: 0.12–5.42), warfarin OR 1.87 (95%CrI: 0.31–6.45); 
major bleed LMWH OR 0.85 (95%CrI: 0.15–2.67), warfarin OR 0.74 (95%CrI: 0.15–2.15). 
No data were available on major bleed for rivaroxaban in people with active can-
cer. cOnclusiOns: There were no significant differences in the outcomes evaluated. 
However, the available evidence suggests that LMWH may have the lowest risk of VTE 
recurrence in the treatments assessed.
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Objectives: To assess the association between adherence to heart failure (HF) 
evidence-based treatment (i.e. β -blocker + angiotension-converting enzyme inhibi-
tor or angiotensin receptor blocker or hydralazine + isosorbide dinitrate), and 1) 
one-year all-cause hospitalization and 2) one-year all-cause mortality, among 
people newly diagnosed for HF. MethOds: We conducted two nested case-control 
studies using Quebec (Canada) medico-administrative data. We selected cases and 
controls in a cohort made of Quebec residents ≥ 18 years who had a first diagnosis 
of HF between 01/01/2000 and 12/31/2009 and who did not use HF evidence-based 
treatment before their diagnosis. Cases were those hospitalized or who died in 
the year after HF diagnosis. Each case was randomly matched to 4 to 10 controls 
using incidence density sampling. Adherence to HF evidence-based treatment 
was assessed using the proportion of days covered (PDC). Odds ratios (OR) were 
calculated using conditional multivariable logistic regressions. Results: Among 
the 125,622 individuals in the cohort, 70,483 (56.1%) were hospitalized and 19,915 
(15.9%) died during the first year after diagnosis. Only 7.5% of hospitalization cases, 
9.5% of their controls, 6.9% of death cases and 11.6% of their controls had a PDC 
≥ 80%. Compared to those with a PDC ≥ 80%, patients who had a PDC > 0% and 
< 80% (OR= 1.39 (95% CI= 1.33-1.46) or a PDC = 0% (OR= 1.53 (1.48-1.58) were more 
likely to be hospitalized within the first year after diagnosis. Similarly, compared 
to those with a PDC ≥ 80%, patients who had a PDC > 0% and < 80% (OR= 1.72 (95% 
CI= 1.59-1.86) or a PDC = 0% (OR= 2.26 (2.13-2.40) were more likely to die during the 
year after diagnosis. cOnclusiOns: Adherence to HF evidence-based treatment 
is suboptimal. A low adherence could increase the risk of hospitalization and have 
a detrimental effect on survival of HF patients.
PCV21
systeMatiC reView aNd Meta-aNalysis of self-MoNitoriNg aNd 
self-MaNageMeNt of aNtiCoagulatioN tHeraPy witH VitaMiN k 
aNtagoNists
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Objectives: The introduction of prothrombin time (INR) point-of-care devices 
permits patient self-testing of the INR values and subsequently, also self-adjust-
ment of the dosing regimen. The purpose of this systematic review was to evaluate 
recent findings regarding the effects of self-monitoring and self-management of 
anticoagulation therapy with vitamin K antagonists (coumarins) compared to the 
standard ambulatory care. MethOds: A comprehensive literature search using 
OVID MEDLINE (1946 – April 2015) and EMBASE (1974 – April 2015) databases was 
performed. Selection criteria were restricted to randomized controlled clinical tri-
als evaluating self-monitoring or self-management with standard care as control. 
Meta-analysis was performed in Review Manager Computer program (Version 
5.3.) using a fixed-effect model with the Mantel-Haenszel method to calculate 
the pooled risk ratios (RR) and their 95% confidence interval (CI) of the following 
clinical outcomes: thromboembolic events, major haemorrhage, and all-cause 
mortality. Potential heterogeneity was assessed with I2 statistics. Results: In 
addition to the 2010 Cochrane review (Self-monitoring and self-management of 
oral anticoagulation), 10 novel randomized trials were identified; in 3 of them 
self-monitoring was evaluated, while in the other 7 studies self-management 
was assessed. Until the April 2015, self-monitoring and self-management was 
evaluated in 10 (4313 participants) and 19 (5413 participants) randomized tri-
als, respectively. Self-management was associated with significant reductions in 
both thromboembolic events (RR= 0.48, 95%CI: 0.35–0.65, p< 0.001) and mortality 
(RR= 0.70, 95%CI: 0.49–0.99, p= 0.046), while no significant effect on major bleedings 
was found (RR= 1.03, 95%CI: 0.77–1.38). In contrast to the 2010 Cochrane review 
no significant benefit of self-monitoring could be confirmed: the RRs were 0.91 
(95%CI: 0.71–1.16), 0.91 (95%CI: 0.75–1.10), and 0.94 (95%CI: 0.75–1.17) for the throm-
boembolic events, major bleedings, and mortality, respectively. cOnclusiOns: 
Compared to the standard ambulatory care, patient self-management of the INR 
values shows beneficial effects on their anticoagulant therapy. Moreover, self-
management better improves the probability of the occurrence of thromboembolic 
events than self-monitoring.
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lower tendency of bleeding and in reducing stroke incidences. This study aims to 
compare the pattern of anticoagulants used and to assess their safety and efficacy 
by evaluating bleeding and stroke occurrences in both groups. MethOds: This is a 
retrospective study carried out at a hospital with hematology clinic in the state of 
Selangor, Malaysia. The samples of the study were patients with atrial fibrillation, 
prescribed with warfarin or dabigatran. Data collected includes patients’ demo-
graphics, co-morbidities, and stroke and haemorrhage events. Results: A total of 
71 patients were recruited in this study with 21, 21 and 29 patients were on Warfarin, 
Dabigatran 110 mg and Dabigatran 150 mg respectively. Out of 50 Dabigatran users, 
36 of them are warfarin-experienced. 1 out of 21 patients on warfarin experienced 
stroke while none in both 110 and 150mg dabigatran group. A total of 11 (52.4%) 
of warfarin patients experienced bleeding with 2 of them having major bleeding 
whereas, only 4 (8%) out of 50 dabigatran patients experienced minor bleeding, 
1 in patient who were on Dabigatran 150mg and 3 patients who were on Dabigatran 
110mg. cOnclusiOns: The pattern of anticoagulant used for stroke prophylaxis 
in atrial fibrillation is slowly changing from Warfarin to Dabigatran. Evaluation of 
safety and efficacy profile of Warfarin shows that Warfarin requires more extensive 
management and monitoring in order to achieve therapeutic goals with fewer side 
effects. Comparison between both anticoagulants show that Dabigatran is safer and 
more effective compared to warfarin.
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Co-adMiNistratioN of ProtoN PuMP iNHiBitors iN CHroNiC asPiriN 
users aNd tHe risk of adVerse CardioVasCular eVeNts: a PoPulatioN-
Based CoHort study
Tran-Duy A1, Vanmolkot FH1, Souverein PC2, Hoes AW3, de Boer A2, Stehower CD1, de Wit 
NJ3, Joore MA1, de Vries F2
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Objectives: In patients receiving long-term low-dose aspirin for prevention of 
adverse cardiovascular (CV) events, proton pump inhibitors (PPIs) are often prescribed 
to prevent aspirin-induced gastrointestinal bleeding. However, PPIs may reduce the 
therapeutic efficacy of aspirin. This study investigated the effect of co-administration 
of PPIs in aspirin users with a first acute myocardial infarction (AMI) or stroke on the 
risk of recurrence of such a CV event. MethOds: A retrospective cohort study using 
the Clinical Practice Research Datalink (CPRD) was conducted in patients with at least 
one occurrence of AMI or stroke between 1998 and 2014, and who received at least 
one prescription of aspirin (30-325 mg/day) after the first AMI or stroke. Concomitant 
use of aspirin and PPIs was defined as overlaps between periods of current use of 
aspirin and of PPIs. The hazard ratio (HR; i.e. the instantaneous risk in concomitant 
use of aspirin and PPIs relative to that in aspirin use alone) was estimated using 
a Cox proportional hazards model with time-varying covariates. The estimate was 
adjusted for multiple potential confounders such as age, BMI, socioeconomic status, 
smoking status and history of diabetes. Results: The study population consisted of 
39,794 patients. During the follow-up period [range: 0.0-16.9 years; mean (SD): 4.1 (3.8) 
years], 18,094 patients had no prescription of PPIs, and 13,013 patients concomitantly 
used aspirin and PPIs for a cumulative duration longer than 50% of the cumulative 
duration of aspirin use. AMI or stroke recurred in 4,307 patients, with mean (SD) time 
from the first to the second event being 2.6 (2.7) years. Adjusted HR (95% CI) of AMI 
or stroke in aspirin plus PPIs versus aspirin use was 1.23 (1.07-1.41). cOnclusiOns: 
Co-administration of PPIs in aspirin users with a first AMI or stroke is associated with 
an increased risk of recurrence of such a CV event.
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Objectives: The management of SI in patients at high CV risk is poorly understood 
within Canada. The present study was conducted to describe SI patient characteris-
tics and their management and to estimate the incidence in the high-risk popula-
tion. MethOds: We retrospectively analysed data from an open cohort of patients 
initiating statin therapy between 2004 and 2012, using the Southwestern Ontario 
primary-care practice database. Inclusion criteria were: diagnosis of dyslipidaemia, ≥ 1 
statin prescription, and ≥ 2 years of statin-free baseline data. SI index date was identi-
fied as the first occurrence of SI-related symptoms associated with a change in statin 
therapy. Patients were stratified into three CV risk levels (low, intermediate, high). 
Here, we report results for the high-risk subgroup. Results: Of 41,733 patients who 
initiated statin therapy, 14,607 were at high CV risk; 1,294 patients in this subgroup 
had SI. The mean±SD age was 61±8.9 years, 53% (n= 684) were male, and low-density 
lipoprotein cholesterol (LDL-C) was 2.8±1.1 mmol/L. Among patients identified with 
SI, 13% (n= 170) experienced myopathy and 87% (n= 1124) had SI-related symptoms. 
There were nine rhabdomyolysis cases, two resulting in hospitalization. Statins were 
discontinued in 412 (32%) patients, and 677 (52%) patients had their statin dosage 
decreased. At the SI index date 84% (n= 1085) of patients were on LDL-C target, with 
the on-target proportion decreasing to 49% (n= 638) 6 months post-SI. Among the 656 
patients off-target at 6 months post-SI, 28% (n= 185) decreased statin dose or stopped 
statins, and 46% (n= 299) were switched to a non-statin therapy. cOnclusiOns: SI 
affects the optimal treatment of dyslipidaemia in this high-risk population. A number 
of patients do not achieve their LDL-C target and are undertreated because they do 
not tolerate their initial statin dose or have to be treated with a non-statin therapy. 
These patients are at increased CV risk.
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a oNe-year follow-uP of PatieNts witH aCute CoroNary syNdroMe 
(aCs) aNd diaBetes treated witH statiNs: outCoMes aNd HealtH Care 
Costs suPPorted By italiaN NatioNal HealtH serViCe
Maggioni AP1, Rossi E2, Cinconze E2, Calabria S3
with and without a new CVE between 01/01/2006 and 06/30/2012. CVEs included pri-
mary inpatient claims for myocardial infarction (MI), unstable angina (UA), ischemic 
stroke (IS), transient ischemic attack, revascularization and heart failure. Patients 
were stratified into two CV risk cohorts: history of cardiovascular disease (CVD) [MI, 
UA, coronary artery bypass graft, percutaneous coronary intervention, IS] and coro-
nary heart disease risk equivalent (CHD RE) [peripheral artery disease, abdominal 
aortic aneurysm, coronary artery disease, diabetes, dyslipidemia]. Propensity score 
matching was applied to compare the burden among patients with and without a 
new CVE, ranging from 1 month through 3 years post-CVE date. cOnclusiOns: 
High-risk hyperlipidemia patients with new CVEs had significantly higher burden of 
hospitalizations and healthcare visits compared to matched patients without new 
CVEs, evident in the 1st month and sustained through 3 years post-CVE.
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aNtiCoagulaNts iN a PoPulatioN-Based CoHort of New users witH 
atrial fiBrillatioN
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Objectives: To compare the effectiveness and safety of oral anticoagulants (OACs) 
-NOAC and VKA- in patients with atrial fibrillation (AF) in real-world clinical prac-
tice. MethOds: Retrospective population-based cohort study. All new users of OAC 
from Nov2011 to Feb2014 with AF were included (N= 21841). Data were obtained by 
linking diverse electronic databases of the Valencia Region, Spain. Incidence rates 
were estimated. Cox proportional hazards models adjusted for sociodemographic, 
clinical, healthcare use data, and propensity scores assessed the risk of several 
outcomes on effectiveness and safety of each NOAC compared with acenocumarol. 
Apixaban and warfarin patients were excluded because of few person-time obser-
vations Results: The incidence of ischemic stroke was 12.5, 8.7 and 10.8 per 1000 
person-years for acenocumarol, dabigatran and rivaroxaban. After adjustment 
no differences were found for NOAC in the risk of ischemic stroke compared to 
acenocumarol (HR:0.78, 95%CI:0.51-1.20 for dabigatran; HR:0.76, 95%CI:0.42-1.35 
for rivaroxaban). Regarding the incidence of mortality (80.2, 65.1 and 91.7, respec-
tively) no increased risk was found (HR:0.96, 95%CI:0.81-1.12 for dabigatran; HR: 1.16, 
95%CI:0.95-1.42 for rivaroxaban). The incidence of gastrointestinal bleeding was 18.3, 
21.4 and 14.4, respectively, being dabigatran associated with a higher risk (HR:1.44, 
95%CI:1.08-1.92) but not rivaroxaban (HR: 0.72, 95%CI: 0.43-1.19). However, no dif-
ferences were found for major gastrointestinal bleeding (HR: 1.01, 95%CI: 0.59-1.73 
for dabigatran; HR:0.43, 95%CI:0.16-1.17 for rivaroxaban). Regarding the incidence 
of intracranial haemorrhage (8.8, 3.0 and 5.4, respectively), dabigatran was found to 
be associated with a decreased risk (HR:0.36, 95%CI:0.18-0.74), and no differences 
for rivaroxaban (HR: 0.56, 95%CI 0.25-1.27). cOnclusiOns: NOAC were not associ-
ated with an increased risk of stroke or death compared with acenocumarol among 
newly treated patients with AF. Dabigatran was associated with lower risk of intrac-
ranial haemorrhage and higher risk of gastrointestinal bleeding. The risk of major 
gastrointestinal bleeding related to NOAC was similar to that for acenocumarol.
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Objectives: Warfarin is an oral anticoagulant prescribed as prophylaxis for patients 
with high risk of developing thrombosis, pulmonary embolism as well as treatment 
for recurrent and idiopathic incident of pulmonary embolism. This study aims to 
compare time in therapeutic range (TTR) of warfarin in patients with pulmonary 
embolism with bleeding and stroke and determine reasons of INR falling out of 
range. MethOds: This is a retrospective study carried out at a tertiary-care hospital 
with anticoagulation clinic in the state of Selangor, Malaysia. The samples of the 
study were patients with pulmonary embolism, prescribed with warfarin from year 
2009 to 2014. The data collected includes patients’ demographics, co-morbidities, 
and international normalized ratio (INR). TTR was determined using Rosendaal 
method. Patients’ stroke, haemorrhage events and reasons of INR being outside the 
range were recorded. Results: TTR of 20 out of 30 patients (66.67%) were found to 
be outside the range (< 75%) with 8 of them (40%) experiencing bleeding. The remain-
ing 10 patients (33.33%) recorded TTR of more than 75%, where 3 of them (30%) 
experienced bleeding during their warfarin treatment. Out of the total 11 patients 
who bled, 10 of them had minor bleeding. The other 1 patient from TTR < 75% group 
had major bleeding. None of the patients from both groups experienced stroke. The 
highest identified reason of International Normalized Range (INR) being outside 
the range was found to be drug-drug interactions, which were seen in 9 patients 
(30%). cOnclusiOns: Warfarin treatment should be maintained within the tar-
geted INR range to avoid unwanted events such as bleeding and stroke. Based on the 
findings of this study, it can be concluded that warfarin monitoring should be done 
continuously and thoroughly to ensure that INR level falls within the targeted range.
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PreliMiNary study of safety aNd effiCaCy of warfariN Versus 
daBigatraN iN atrial fiBrillatioN PatieNts iN a tertiary HosPital iN 
Malaysia
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Objectives: Warfarin has been used for more than 50 years as stroke prophylaxis 
in patients with atrial fibrillation. New oral anticoagulant, Dabigatran, was devel-
oped and shown to be safer and more efficacious compared to Warfarin due to its 
